China Dasheng Biotechnology Company

Total Valuation

China Dasheng Biotechnology Company carries a market capitalization of 4.10M, placing it among publicly traded companies globally. Its enterprise value stands at 24.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

China Dasheng Biotechnology Company currently has 30.00M shares outstanding.

Valuation Ratios

China Dasheng Biotechnology Company trades at a trailing price-to-earnings ratio of 4.68. The price-to-sales ratio is 1.43, and the price-to-book ratio stands at 2.11.

Enterprise Valuation

On an enterprise value basis, China Dasheng Biotechnology Company trades at an EV/EBITDA multiple of 3.17 and an EV/FCF ratio of 2.49. The EV/Sales ratio of 1.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.48 provides insight into valuation relative to core operating earnings.

Financial Position

China Dasheng Biotechnology Company maintains a current ratio of 6.63, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

China Dasheng Biotechnology Company posts a return on equity of 140.08 and a return on invested capital of 58.50.

Stock Price Statistics

China Dasheng Biotechnology Company's stock has gained approximately 35.13514% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.06.

Income Statement

Over the trailing twelve months, China Dasheng Biotechnology Company generated 20.95M in revenue and converted that into 6.41M in net income, yielding earnings per share of 0.22. EBITDA reached 7.72M, while operating income came in at 7.04M.

Balance Sheet

China Dasheng Biotechnology Company holds 10.41M in cash and equivalents against 1.46M in total debt, resulting in a net debt position of -8.95M. Total book value stands at 14.24M, with working capital of 12.54M providing operational flexibility.

Cash Flow

China Dasheng Biotechnology Company produced 9.83M in operating cash flow over the past twelve months. After subtracting -2,278.00 in capital expenditures, free cash flow totaled 9.82M - equivalent to 0.33 per share.

Margins

China Dasheng Biotechnology Company operates with a gross margin of 47.85, reflecting its pricing power and cost economics. The operating margin of 33.59 and net profit margin of 30.58 provide insight into operational efficiency.

Dividends & Yields

Scores

China Dasheng Biotechnology Company posts an Altman Z-Score of 8.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.